Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Crystal Denlinger, MD
Fox Chase Cancer Center
Principal Investigator - Keedy L Vicki, MD
Vanderbilt University Medical Center
Principal Investigator - Kwok Kin Wong, MD
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- the Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2008
- Primary completion
- 31 May 2010
- Completion
- 30 Sept 2013
- Last update posted
- 1 Sept 2016
- Registered enrollment
- 44
- Registry id
- NCT00734305
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.